Skip to main content
. 2016 Oct 31;113(46):E7260–E7267. doi: 10.1073/pnas.1610970113

Fig. 5.

Fig. 5.

Synergy of JAK1 inhibition and ibrutinib in killing of ABC DLBCL cells. (A) The indicated DLBCL lines were treated with the indicated concentrations of AZD1480 and/or ibrutinib for 6 d and evaluated for viability by trypan blue dye exclusion. Both drugs were replenished on day 3. Error bars represent mean ± SD of triplicates. The GCB DLBCL cell line OCI-Ly19 served as a negative control cell line. Data are normalized to toxicity of treatment with the indicated concentrations of ibrutinib alone. A shift of the AZD1480 toxicity curves to the left indicates a greater than additive effect of the two drugs. (B) Ibrutinib increases JAK1 shRNA toxicity in TMD8 and OCI-Ly10 cells. Flow cytometric analysis of the percentage of viable, shJAK1-expressing cells in the presence of 5 nM ibrutinib or DMSO. (C) Immunoblot analysis of the indicated proteins in OCI-Ly10 ABC DLBCL cells after 48 h of treatment with the indicated concentrations of AZD1480 ± 1 nM ibrutinib. Shown below are IRF4 and MYD88 protein levels relative to β-actin levels as quantified by densitometry.